Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of DNL151 in Parkinson's Disease
NCT04056689Phase 1Completed
- Sponsor
- Biogen
- Start
- Jul 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of BIIB122 in Parkinson's disease (PD) (4 arms), sponsored by Biogen. Primary endpoints: Treatment-Emergent Adverse Events at Day 42, Laboratory Test Abnormalities at Day 42 and 3 more. Started Jul 2019; status: completed.
02
Drugs
BIIB122
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04056689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04056689.